Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib

Benzer Materyaller

• Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?
  Yazar:: Green, John A.
  Baskı/Yayın Bilgisi: (2018)
• Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI
  Yazar:: Okuma, Yusuke, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
  Yazar:: Passiglia, Francesco, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
  Yazar:: Jeong, Byeong-Ho, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib
  Yazar:: Kensuke Kanaoka, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-09-01)